American Regent vs. Gland Pharma: Consent Judgment in Trace Elements Patent Dispute
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | American Regent, Inc. v. Gland Pharma Ltd. |
| Case Number | 2:24-cv-07756-BRM-CLW (D.N.J.) |
| Court | U.S. District Court for the District of New Jersey |
| Duration | Jul 2024 – Apr 2025 262 days |
| Outcome | Plaintiff Win – Permanent Injunction |
| Patents at Issue | |
| Accused Products | Gland Pharma’s Trace Elements Injection (ANDA No. 219632) |
Case Overview
The Parties
⚖️ Plaintiff
U.S.-based specialty pharmaceutical company focused on injectable products, including parenteral nutrition and iron replacement therapies. Holds a robust IP portfolio protecting its branded trace elements injection products Tralement® and Multrys®.
🛡️ Defendant
India-headquartered, globally operating generic injectable pharmaceutical manufacturer. Sought FDA approval to market a generic version of ARI’s trace elements injection products via ANDA No. 219632.
Patents at Issue
This case involved five U.S. patents asserted by ARI, collectively protecting formulation, dosing, and/or manufacturing aspects of sterile trace elements injection products used in intravenous parenteral nutrition therapy:
- • US 11,786,548 — Covering formulation, dosing, and/or manufacturing aspects
- • US 11,975,022 — Covering formulation, dosing, and/or manufacturing aspects
- • US 11,998,565 — Covering formulation, dosing, and/or manufacturing aspects
- • US 12,150,956 — Covering formulation, dosing, and/or manufacturing aspects
- • US 12,150,957 — Covering formulation, dosing, and/or manufacturing aspects
Developing a similar drug product?
Check if your pharmaceutical formulation might infringe these or related patents.
The Verdict & Legal Analysis
Outcome
On April 3, 2025, the U.S. District Court for the District of New Jersey entered a **Consent Judgment** resolving Civil Action No. 2:24-cv-07756-BRM-CLW. The court entered an **agreed permanent injunction** against Gland Pharma, preventing them from making, using, selling, offering to sell, importing, or distributing any GLAND Product(s) in the United States, unless specifically authorized or under safe harbor provisions.
Key Legal Issues
This case, brought as a pharmaceutical patent infringement action under the **Hatch-Waxman Act**, reinforces several key doctrinal and procedural realities. The assertion of five patents across a single drug product highlights how **portfolio depth matters**, creating substantial litigation burden for ANDA filers and increasing the probability of early settlement. Furthermore, the use of **consent judgments with carve-out provisions** remains a dominant resolution mechanism, balancing brand holder protection with generic pipeline preservation.
Filing a new drug patent?
Learn from this case. Use AI to draft stronger claims for your drug products that can withstand Hatch-Waxman litigation.
Power Your Patent Strategy with Eureka IP
From novelty searches to patent drafting, Eureka’s AI-powered tools help you navigate the patent landscape with confidence.
⚠️ Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in the injectable pharmaceutical space. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View all 5 related patents in this technology space
- See ANDA litigation trends and settlement patterns
- Understand Hatch-Waxman strategy implications
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own technology or product.
- Input your product description or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Injectable trace elements formulations
5 Patents Asserted
Covering formulation, dosing, manufacturing
Early Resolution Trend
Dominant in multi-patent ANDA cases
✅ Key Takeaways
For Patent Attorneys & Litigators
Multi-patent assertion strategies (five patents here) significantly increase settlement leverage in ANDA litigation.
Search related case law →Consent judgments with Paragraph IV carve-outs are the preferred resolution structure in Hatch-Waxman disputes.
Explore Hatch-Waxman precedents →For R&D Teams
Conduct comprehensive FTO analysis covering all pending continuations before investing in ANDA development for parenteral nutrition products.
Start FTO analysis for my product →Patent families with multiple recently issued patents (2023–2024) indicate aggressive prosecution pipelines that increase generic entry risk.
Try AI patent drafting →Ready to Strengthen Your Patent Strategy?
Join thousands of IP professionals using Eureka to conduct prior art searches, draft patents, and analyze competitive landscapes.